Tectonic Therapeutic, Inc. (TECX) earnings date
Mar 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 62% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 15 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Thu, Mar 20, 2025 | after close | 79 | 8-K |
| Q3 FY2024 | Thu, Nov 7, 2024 | after close | 38 | 8-K |
What they guided beta
| Q2 FY2026 | "Cash and cash equivalents were $227.1 million as of June 30, 2026, including approximately $11.7 million in net proceeds raised from an at-the-market offering for the three months ended June 30, 2026, is expected to provide cash runway into Q1 2029 WATERTOWN, Mass., August 6, 2026 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for t" exhibit |
| Q2 FY2026 | "In July 2026, the Independent Data Monitoring Committee (“IDMC”) met to review unblinded safety and efficacy data from the TX45 APEX Phase 2 clinical trial, including approximately 80% of the expected patient exposure." exhibit |
| Q2 FY2026 | "TX2100 Phase 1a Topline Results Expected by End of Q3 2026 with Phase 2 Planned in Early 2027: The Company expects to report topline results for the TX2100 Phase 1a clinical trial in healthy volunteers by the end of Q3 2026, with detailed data planned to be subsequently presented at a scientific meeting." exhibit |
| Q2 FY2026 | "TX45 APEX Phase 2 Trial Ongoing with Topline Results Expected Early Q1 2027: The global, randomized, placebo-controlled 24-week APEX Phase 2 trial is ongoing, evaluating subcutaneous TX45 in patients with PH-HFpEF, including an enriched population with combined pre- and post-capillary pulmonary hypertension (CpcPH)." exhibit |
| Q2 FY2026 | "APEX patient enrollment is complete with topline results expected early Q1 2027." exhibit |
| Q1 FY2026 | "TX2100 advanced into Phase 1a healthy volunteer clinical trial in February 2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (“HHT”), and as of April 2026, four cohorts have been dosed with topline results expected by the end of Q3 2026" exhibit |
| Q1 FY2026 | "Cash and cash equivalents were $236.9 million as of March 31, 2026, expected to provide cash runway into Q4 2028 WATERTOWN, Mass., May 7, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2026, and provided an overview of recent business highlights." exhibit |
| Q1 FY2026 | "TX2100 Phase 1a Results Expected in 3Q 2026 with Phase 2 Planned in Early 2027: The Company now expects to report topline results from the ongoing Phase 1a trial of TX2100 in healthy volunteers by the end of the third quarter of 2026." exhibit |
| Q1 FY2026 | "proof-of-concept trial in patients with moderate-to-severe HHT in early 2027, with endpoints expected to include epistaxis, anemia and hematologic support, and other HHT measures." exhibit |
| Q1 FY2026 | "TX45 APEX Phase 2 Trial Ongoing with Results Expected Late Q4 2026 or Early Q1 2027: The global, randomized, placebo-controlled 24-week APEX Phase 2 trial is ongoing, evaluating subcutaneous TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), including an enriched population with combined pre- and post-capillary pulmonary hypertension (CpcPH)." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TECX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TECX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TECX/"><img src="https://veritasdata.dev/embed/TECX.svg" alt="TECX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TECX/)
Script
<script async src="https://veritasdata.dev/embed/TECX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TECX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.